LANGLEY PORTER PSYCHIATRIC HOSPITAL

Type: Teaching hospital
Where: San Francisco, CA
Medicare CCN: 054144
Received: $69,746,988 in 2,915 records, 2020 ($11,507,982 general, $58,239,006 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2020	General payment	374	$11,507,982
2020	Research payment	2,541	$58,239,006

By company

Company	Records	Amount	Years
Genentech, Inc.	169	$11,942,068	2020
Merck Sharp & Dohme LLC	406	$6,093,432	2020
Abbott Laboratories	234	$5,765,376	2020
Gilead Sciences, Inc.	100	$4,456,789	2020
Novartis Pharmaceuticals Corporation	43	$4,212,601	2020
PFIZER INC.	180	$2,732,345	2020
F. Hoffmann-La Roche AG	31	$2,585,446	2020
E.R. Squibb & Sons, L.L.C.	32	$2,576,717	2020
ABBVIE INC.	150	$2,523,275	2020
Biogen, Inc.	19	$2,293,597	2020
Celgene Corporation	9	$1,573,013	2020
Eli Lilly and Company	32	$1,509,158	2020
AstraZeneca Pharmaceuticals LP	30	$1,347,675	2020
Novo Nordisk US Research & Development, Inc.	5	$1,117,508	2020
AstraZeneca UK Limited	4	$1,110,562	2020
SEAGEN INC.	18	$1,038,656	2020
Amgen Inc.	20	$950,945	2020
Takeda Pharmaceuticals U.S.A., Inc.	88	$924,222	2020
Janssen Research & Development, LLC	57	$842,180	2020
LEO Pharma AS	3	$752,889	2020
Roche Products Limited	35	$669,570	2020
Neurocrine BioSciences, Inc.	42	$615,033	2020
Incyte Corporation	204	$608,087	2020
Novo Nordisk AS	4	$577,342	2020
Varian Medical Systems, Inc.	6	$482,727	2020
Agios Pharmaceuticals, Inc.	48	$465,818	2020
ROCHE MOLECULAR SYSTEMS, INC.	5	$424,506	2020
Ipsen Biopharmaceuticals, Inc	9	$423,142	2020
JAZZ PHARMACEUTICALS INC.	22	$422,727	2020
BioMarin Pharmaceutical Inc.	36	$387,192	2020
Regeneron Pharmaceuticals, Inc.	23	$362,989	2020
Boston Scientific Corporation	17	$348,778	2020
Siemens Medical Solutions USA, Inc.	16	$333,447	2020
Becton, Dickinson and Company	2	$317,372	2020
Allergan, Inc.	53	$269,512	2020
UCB, Inc.	1	$259,299	2020
Mallinckrodt Hospital Products Inc.	12	$238,556	2020
Synthes GmbH	12	$235,000	2020
Daiichi Sankyo Inc.	50	$224,960	2020
Eisai Inc.	28	$213,759	2020
SANOFI US SERVICES INC.	19	$211,116	2020
GE HEALTHCARE	10	$200,457	2020
Vanda Pharmaceuticals Inc.	1	$189,400	2020
Kadmon Corporation LLC	3	$182,485	2020
PUMA BIOTECHNOLOGY, INC.	9	$178,098	2020
Alnylam Pharmaceuticals Inc.	17	$170,001	2020
Janssen Biotech, Inc.	3	$165,482	2020
Genentech USA, Inc.	6	$165,195	2020
Partner Therapeutics, Inc.	2	$155,142	2020
Roche TCRC, Inc.	27	$150,445	2020

By nature of payment

Nature	Records	Amount
Research payment	2,541	$58,239,006
Grant	96	$8,199,052
Consulting Fee	17	$2,022,434
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	64	$346,830
Education	69	$329,918
Royalty or License	29	$291,653
Space rental or facility fees (teaching hospital only)	86	$262,100
Charitable Contribution	12	$48,994
Honoraria	1	$7,000

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Gilead Sciences, Inc.	$180,333	Grant	Cash or cash equivalent			2020
2020-12-31	ABBVIE INC.	$32,268	Research payment	Cash or cash equivalent	RINVOQ Drug, IMMUNOLOGY	M14-430	2020
2020-12-31	Siemens Medical Solutions USA, Inc.	$16,450	Research payment	Cash or cash equivalent	SC2000 Device, US - Ultrasound Systems	C SC2000 K Systems ECE and ECV	2020
2020-12-31	Roche Diagnostics Operations, Inc.	$14,159	Research payment	In-kind items and services	CD cobas Reagents Device, Centralized Diagnostics	RD005298	2020
2020-12-31	Allergan, Inc.	$9,287	Research payment	In-kind items and services		Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Uniocular Intravitreal RST-001 in Patients	2020
2020-12-31	KARL STORZ Endoscopy-America	$7,683	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$7,419	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$6,151	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$6,002	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$6,002	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Janssen Research & Development, LLC	$5,973	Research payment	Cash or cash equivalent		Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus	2020
2020-12-31	KARL STORZ Endoscopy-America	$5,696	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$5,696	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Roche Diagnostics Operations, Inc.	$5,655	Research payment	Cash or cash equivalent	CD cobas Reagents Device, Centralized Diagnostics	RD005298	2020
2020-12-31	KARL STORZ Endoscopy-America	$5,264	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$4,707	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$4,444	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$4,125	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	GE HEALTHCARE	$4,078	Research payment	Cash or cash equivalent	Device, MAGNETIC RESONANCE	KNEE AND PATELLOFEMORAL OVERLOAD AND ARTICULAR CARTILAGE INJURIES THE ADVANCED IMAGING PROTOCOL STUDY	2020
2020-12-31	KARL STORZ Endoscopy-America	$3,809	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$3,744	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Daiichi Sankyo Inc.	$3,325	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$3,117	Research payment	In-kind items and services		Multiarm Open label multicenter phase 1b 2 study to evaluate novel combination therapies in subjects with previously tre	2020
2020-12-31	KARL STORZ Endoscopy-America	$2,802	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$2,661	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$2,661	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$2,508	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$1,927	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Daiichi Sankyo Inc.	$1,600	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	Daiichi Sankyo Inc.	$1,330	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$1,149	Research payment	In-kind items and services		This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus	2020
2020-12-31	Daiichi Sankyo Inc.	$1,020	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$978	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla	2020
2020-12-31	KARL STORZ Endoscopy-America	$940	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$940	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$940	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$935	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$910	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$818	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$713	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$713	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	AstraZeneca UK Limited	$648	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa	2020
2020-12-31	KARL STORZ Endoscopy-America	$618	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$618	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$618	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$618	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$579	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$579	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$508	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$393	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$363	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$360	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$360	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$360	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$329	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$309	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$309	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$309	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$212	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$212	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$212	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Daiichi Sankyo Inc.	$200	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	Daiichi Sankyo Inc.	$200	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	Daiichi Sankyo Inc.	$200	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-31	KARL STORZ Endoscopy-America	$164	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	Masimo Corporation	$158	Education	In-kind items and services	SedLine Device, Devices		2020
2020-12-31	KARL STORZ Endoscopy-America	$147	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$147	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$147	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$145	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$87	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$75	Education	In-kind items and services	IMAGE 1,H3-Z HEAD,ZOOM,50/60HZ,CE Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$75	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Siemens Medical Solutions USA, Inc.	$28	Charitable Contribution	In-kind items and services			2020
2020-12-31	KARL STORZ Endoscopy-America	$22	Education	In-kind items and services	3D GLASSES, PASSIVE, POLARIZED Device, VIDEOIMAGING		2020
2020-12-31	Aimmune Therapeutics, Inc.	$18	Research payment	Cash or cash equivalent	PALFORZIA Biological, ALLERGY	A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS	2020
2020-12-30	ABBVIE INC.	$26,883	Research payment	Cash or cash equivalent		M15-570	2020
2020-12-30	ABBVIE INC.	$8,219	Research payment	Cash or cash equivalent	VENCLEXTA Drug, ONCOLOGY	M13-833	2020
2020-12-30	ABBVIE INC.	$4,596	Research payment	Cash or cash equivalent	SKYRIZI Biological, IMMUNOLOGY	M16-006	2020
2020-12-30	Abbott Laboratories	$3,151	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Architect system Device, Diagnostics		2020
2020-12-30	ABBVIE INC.	$2,715	Research payment	Cash or cash equivalent	VENCLEXTA Drug, ONCOLOGY	M16-802	2020
2020-12-30	Incyte Corporation	$840	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-30	Merck Sharp & Dohme LLC	$711	Research payment	Cash or cash equivalent	MK-7339 Drug, ONCOLOGY	A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb	2020
2020-12-30	Abbott Laboratories	$157	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Architect system Device, Diagnostics		2020
2020-12-30	ABBVIE INC.	$75	Research payment	Cash or cash equivalent	SKYRIZI Biological, IMMUNOLOGY	M16-000	2020
2020-12-29	ABBVIE INC.	$50,000	Research payment	Cash or cash equivalent			2020
2020-12-29	BeiGene, Ltd.	$22,500	Research payment	Cash or cash equivalent		PNOC017	2020
2020-12-29	Genentech, Inc.	$17,881	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH IA IB PERSONALIZED CANCER VACCINE ATEZOLIZUMABB	2020
2020-12-29	BioMarin Pharmaceutical Inc.	$13,697	Research payment	Cash or cash equivalent		A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop	2020
2020-12-29	PFIZER INC.	$2,634	Research payment	Cash or cash equivalent		A PHASE 12 OPENLABEL ADAPTIVE DOSERANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB525 PF07055480 RECOMBINANT AA	2020
2020-12-29	F. Hoffmann-La Roche AG	$1,585	Research payment	Cash or cash equivalent	COTELLIC Drug, BioOncology	PHASE I IN AML WITH VENETOCLAX COBI MDM2	2020
2020-12-29	Incyte Corporation	$840	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-28	Biohaven Pharmaceuticals, Inc.	$58,682	Research payment	Cash or cash equivalent		A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebella	2020
2020-12-28	Merck Sharp & Dohme LLC	$19,541	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2020
2020-12-28	Aimmune Therapeutics, Inc.	$2,154	Research payment	Cash or cash equivalent	PALFORZIA Biological, ALLERGY	A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS	2020
2020-12-28	Incyte Corporation	$525	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-24	Allergan, Inc.	$11,657	Research payment	Cash or cash equivalent		AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o	2020
2020-12-24	Merck Sharp & Dohme LLC	$1,500	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection	2020
2020-12-24	Allergan, Inc.	$834	Research payment	Cash or cash equivalent		AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o	2020
2020-12-23	SEAGEN INC.	$117,381	Research payment	Cash or cash equivalent	PADCEV Biological, Oncology	A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che	2020
2020-12-23	Intercept Pharmaceuticals, Inc.	$24,110	Research payment	Cash or cash equivalent	OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY	1011866	2020
2020-12-23	Neurocrine BioSciences, Inc.	$17,742	Research payment	Cash or cash equivalent		A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY	2020
2020-12-23	Gilead Sciences, Inc.	$7,676	Research payment	Cash or cash equivalent		A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof	2020
2020-12-23	ROCHE MOLECULAR SYSTEMS, INC.	$6,650	Research payment	Cash or cash equivalent	COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics	RD005156	2020
2020-12-23	Neurocrine BioSciences, Inc.	$4,987	Research payment	Cash or cash equivalent		A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY	2020
2020-12-23	UCB SA	$3,950	Research payment	Cash or cash equivalent		A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT	2020
2020-12-23	EMD Serono, Inc.	$3,621	Research payment	Cash or cash equivalent		UCSF Egg Freezing Study (oEuFS) - MS200059_0007	2020
2020-12-23	Gilead Sciences, Inc.	$2,358	Research payment	Cash or cash equivalent	Vemlidy Drug, HBV	A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala	2020
2020-12-23	Gilead Sciences, Inc.	$1,747	Research payment	Cash or cash equivalent	Vemlidy Drug, HBV	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD v	2020
2020-12-23	PFIZER INC.	$1,299	Research payment	Cash or cash equivalent	VYNDAQEL Drug, CARDIOVASCULAR	A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME	2020
2020-12-23	Gilead Sciences, Inc.	$1,149	Research payment	Cash or cash equivalent		A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-96	2020
2020-12-23	Neurocrine BioSciences, Inc.	$1,017	Research payment	Cash or cash equivalent		A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY	2020
2020-12-23	Gilead Sciences, Inc.	$990	Research payment	Cash or cash equivalent	Sovaldi Drug, HCV	A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf	2020
2020-12-23	Incyte Corporation	$840	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-23	Boston Scientific Corporation	$100	Charitable Contribution	Cash or cash equivalent			2020
2020-12-22	Genentech, Inc.	$1,654,255	Consulting Fee	Cash or cash equivalent	Drug		2020
2020-12-22	Immunomedics, Inc.	$106,677	Research payment	Cash or cash equivalent	Trodelvy Drug, Oncology	IMMU-132-05	2020
2020-12-22	LEO Pharma AS	$67,022	Research payment	Cash or cash equivalent			2020
2020-12-22	PUMA BIOTECHNOLOGY, INC.	$62,132	Research payment	Cash or cash equivalent	NERLYNX Drug, ONCOLOGY	AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA	2020
2020-12-22	Daiichi Sankyo Inc.	$35,157	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U303	2020
2020-12-22	Genentech, Inc.	$22,924	Research payment	Cash or cash equivalent	ROZLYTREK Biological, BioOncology	STARTRK 2 RXDX 101 02	2020
2020-12-22	Genentech, Inc.	$11,853	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Drug		2020
2020-12-22	E.R. Squibb & Sons, L.L.C.	$11,703	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase I IIA 2L 3L CRC MSS KRAS Nivo MEK Combo trametinib Novartis	2020
2020-12-22	BeiGene, Ltd.	$11,249	Research payment	Cash or cash equivalent		A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT)	2020
2020-12-22	Merck Sharp & Dohme LLC	$6,946	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu	2020
2020-12-22	Alexion Pharmaceuticals, Inc.	$5,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2020
2020-12-22	Incyte Corporation	$3,990	Research payment	Cash or cash equivalent		A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	2020
2020-12-22	Clovis Oncology, Inc.	$3,680	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$3,578	Research payment	Cash or cash equivalent	Mirena Drug, Women's Health	BAY86-5028 Mirena extension contraception	2020
2020-12-22	BeiGene, Ltd.	$2,993	Research payment	Cash or cash equivalent		A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT)	2020
2020-12-22	Daiichi Sankyo Inc.	$2,789	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U303	2020
2020-12-22	Incyte Corporation	$1,020	Research payment	Cash or cash equivalent		A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	2020
2020-12-22	Incyte Corporation	$630	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-22	Incyte Corporation	$448	Research payment	Cash or cash equivalent		A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	2020
2020-12-22	Incyte Corporation	$428	Research payment	Cash or cash equivalent		A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	2020
2020-12-21	Gilead Sciences, Inc.	$76,060	Research payment	Cash or cash equivalent		A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiret	2020
2020-12-21	SANOFI US SERVICES INC.	$45,827	Research payment	Cash or cash equivalent	DUPIXENT Biological, Immunology	A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patie	2020
2020-12-21	Clovis Oncology, Inc.	$31,521	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)	2020
2020-12-21	Eisai Inc.	$29,998	Research payment	Cash or cash equivalent		A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety	2020
2020-12-21	Lilly USA, LLC	$29,832	Research payment	Cash or cash equivalent		A PILOT TRIAL OF GALCANEZUMAB FOR VESTIBULAR MIGRAINE	2020
2020-12-21	Janssen Research & Development, LLC	$6,290	Research payment	Cash or cash equivalent		A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with	2020
2020-12-21	ABBVIE INC.	$4,520	Research payment	Cash or cash equivalent		M15-566	2020
2020-12-21	Abbott Laboratories	$1,464	Research payment	In-kind items and services	I-STAT TBI Device, Diagnostics	Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device	2020
2020-12-21	Incyte Corporation	$840	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-21	Abbott Laboratories	$193	Research payment	In-kind items and services	I-STAT TBI Device, Diagnostics	Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device	2020
2020-12-21	Abbott Laboratories	$193	Research payment	In-kind items and services	I-STAT TBI Device, Diagnostics	Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device	2020
2020-12-18	Janssen Research & Development, LLC	$31,584	Research payment	Cash or cash equivalent		Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus	2020
2020-12-18	Janssen Research & Development, LLC	$22,808	Research payment	Cash or cash equivalent		A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA	2020
2020-12-18	Genentech, Inc.	$10,906	Consulting Fee	Cash or cash equivalent	Drug		2020
2020-12-18	Genentech USA, Inc.	$3,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Activase Biological, Metabolism & Primary Care		2020
2020-12-18	Janssen Research & Development, LLC	$1,900	Research payment	Cash or cash equivalent		Uptravi (Selexipag): the users drug registry	2020
2020-12-18	Janssen Research & Development, LLC	$1,706	Research payment	Cash or cash equivalent		Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez	2020
2020-12-18	Incyte Corporation	$630	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-18	PFIZER INC.	$600	Research payment	Cash or cash equivalent	IBRANCE Drug, ONCOLOGY	PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI	2020
2020-12-18	PFIZER INC.	$500	Research payment	Cash or cash equivalent	IBRANCE Drug, ONCOLOGY	PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI	2020
2020-12-17	Incyte Corporation	$106,978	Research payment	Cash or cash equivalent		Relative Bioavailability of INCB039110 Sustained Release Test Formulations, Evaluation of Immediate Release Formulations	2020
2020-12-17	Incyte Corporation	$76,796	Research payment	Cash or cash equivalent		Relative Bioavailability of INCB039110 Sustained Release Test Formulations, Evaluation of Immediate Release Formulations	2020
2020-12-17	Merck Sharp & Dohme LLC	$32,569	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis	2020
2020-12-17	Stryker Corporation	$21,475	Grant	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-17	Merck Sharp & Dohme LLC	$5,707	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv	2020
2020-12-17	Intercept Pharmaceuticals, Inc.	$5,318	Research payment	Cash or cash equivalent	OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY	1011866	2020
2020-12-17	Cook Research Incorporated	$3,903	Research payment	Cash or cash equivalent	Cook Medical Lead Extraction Device, Lead Management	(16-04) RELEASE: Transvenous Lead Removal using the Cook Evolution LEAd Extraction SystEm	2020
2020-12-17	Deciphera Pharmaceuticals Inc.	$3,122	Research payment	Cash or cash equivalent		A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS	2020
2020-12-17	Exelixis Inc.	$2,825	Research payment	Cash or cash equivalent	Cabozantinib Drug, Oncology	A Randomized, Controlled Phase 3 Study of Cabozantinib XL184) in Combination with Atezolizumab versus Sorafenib in Subje	2020
2020-12-17	Exelixis Inc.	$1,494	Research payment	Cash or cash equivalent	Cabozantinib Drug, Oncology	A Randomized, Controlled Phase 3 Study of Cabozantinib XL184) in Combination with Atezolizumab versus Sorafenib in Subje	2020
2020-12-17	Incyte Corporation	$630	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-17	Medicines360	$180	Research payment	Cash or cash equivalent	Liletta Device, Obstetrics/Gynecology (Women's Health)	A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru	2020
2020-12-17	Merck Sharp & Dohme LLC	$32	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu	2020
2020-12-16	Merck Sharp & Dohme LLC	$694,685	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase II Study of Neoadjuvant Pembrolizumab-Based Combination Therapy in Patients with Locally Advanced or Metastatic	2020
2020-12-16	Roche TCRC, Inc.	$9,992	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS	2020
2020-12-16	Genentech, Inc.	$6,497	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY	2020
2020-12-16	KLS-Martin L.P.	$2,500	Grant	Cash or cash equivalent			2020
2020-12-16	Incyte Corporation	$525	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-16	Merck Sharp & Dohme LLC	$307	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit	2020
2020-12-15	Gilead Sciences, Inc.	$75,000	Research payment	Cash or cash equivalent		Develop a model of SLE disease activity and progression based on DNA methylation profiles.	2020
2020-12-15	Orthofix Medical, Inc.	$10,906	Research payment	Cash or cash equivalent	Physio-Stim Osteogenesis Stimulator Device, Stimulator, Bone Growth, Non-Invasive	CP-1604 PSRC	2020
2020-12-15	Agios Pharmaceuticals, Inc.	$8,134	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects with Re	2020
2020-12-15	BioMarin Pharmaceutical Inc.	$4,637	Research payment	Cash or cash equivalent		An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia	2020
2020-12-15	Agios Pharmaceuticals, Inc.	$3,325	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects with Re	2020
2020-12-15	Agios Pharmaceuticals, Inc.	$1,920	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects with Re	2020
2020-12-15	Agios Pharmaceuticals, Inc.	$1,596	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects with Re	2020
2020-12-15	Abbott Laboratories	$1,464	Research payment	In-kind items and services	I-STAT TBI Device, Diagnostics	Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device	2020
2020-12-15	Incyte Corporation	$525	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-15	Abbott Laboratories	$193	Research payment	In-kind items and services	I-STAT TBI Device, Diagnostics	Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device	2020
2020-12-15	Abbott Laboratories	$193	Research payment	In-kind items and services	I-STAT TBI Device, Diagnostics	Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device	2020
2020-12-14	Gilead Sciences, Inc.	$105,924	Research payment	Cash or cash equivalent		A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiret	2020
2020-12-14	PFIZER INC.	$100,000	Research payment	Cash or cash equivalent	EUCRISA Drug, DERMATOLOGY	IMMUNOPHENOTYPING ADULT ATOPIC DERMATITIS	2020
2020-12-14	PFIZER INC.	$100,000	Research payment	Cash or cash equivalent	EUCRISA Drug, DERMATOLOGY	THE IMPACT OF ATOPIC DERMATITIS ON CAREGIVERS	2020
2020-12-14	SANOFI US SERVICES INC.	$31,858	Research payment	Cash or cash equivalent	DUPIXENT Biological, Immunology	A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patie	2020
2020-12-14	SANOFI US SERVICES INC.	$15,520	Research payment	Cash or cash equivalent	SARCLISA Biological, Oncology	An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patien	2020
2020-12-14	Janssen Research & Development, LLC	$14,158	Research payment	Cash or cash equivalent		An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult	2020
2020-12-14	Merck Sharp & Dohme LLC	$13,027	Research payment	In-kind items and services	MK-1454 Drug, ONCOLOGY	A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate In	2020
2020-12-14	Abbott Laboratories	$5,494	Research payment	Cash or cash equivalent	I STAT Hs TnL Device, Diagnostics	Alinity I STAT hsTnl Design Validation Protocol	2020
2020-12-14	Genentech, Inc.	$3,372	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD	2020
2020-12-14	Genentech, Inc.	$572	Research payment	Cash or cash equivalent	Avastin Biological, BioOncology	IMMOTION 151 APDL1 IN RENAL CELL CARCINOMA RCC	2020
2020-12-14	Incyte Corporation	$525	Research payment	In-kind items and services		A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr	2020
2020-12-12	Allergan, Inc.	$2,500	Education	Cash or cash equivalent	COMBIGAN Drug, OPHTHALMOLOGY		2020
2020-12-12	Merck Sharp & Dohme LLC	$1,109	Research payment	In-kind items and services	MK-4830 Biological, ONCOLOGY	A Phase 1, Open-label, Multi-Arm, Multi-Site Study of MK-4830 anti-ILT4 as Monotherapy and in Combination with Pembroliz	2020
2020-12-11	Neurocrine BioSciences, Inc.	$65,413	Research payment	Cash or cash equivalent		A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY	2020
2020-12-11	Merck Sharp & Dohme LLC	$20,225	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis	2020

The latest 200 records of 2,915.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

Measure	Place (city or town) San Francisco, CA	County San Francisco County, CA	State California
Population B01003	830,235	830,235	39,287,377
Population, 2020 census P1	873,965	873,965	39,538,223
Median age B01002	40.0	40.0	37.9
Under 18 B01001	13.7%	13.7%	22.0%
65 and over B01001	17.6%	17.6%	15.7%
Households B11001	363,970	363,970	13,548,091
Foreign born B05002	34.0%	34.0%	27.0%
Median household income B19013	$140,970	$140,970	$99,122
Median family income B19113	$171,141	$171,141	$113,346
Per capita income B19301	$92,289	$92,289	$49,513
Poverty rate B17001	11.2%	11.2%	12.0%
Unemployment rate B23025	6.1%	6.1%	6.6%
Civilian labor force B23025	507,262	507,262	20,068,466
Mean commute (minutes) B08013	30.4	30.4	28.7
Bachelor's degree or higher B15003	60.3%	60.3%	37.1%
Housing units B25001	414,602	414,602	14,644,735
Owner-occupied B25003	38.2%	38.2%	55.9%
Renters B25003	61.8%	61.8%	44.1%
Median home value B25077	$1,394,500	$1,394,500	$734,700
Median gross rent B25064	$2,476	$2,476	$2,036
White, not Hispanic B03002	36.8%	36.8%	33.8%
Black B03002	4.7%	4.7%	5.2%
Hispanic or Latino B03002	16.2%	16.2%	40.2%
Asian B03002	34.9%	34.9%	15.3%
American Indian and Alaska Native B03002	0.2%	0.2%	0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.